ME1 and hyperphosphatemia: 2004; Loriot et al. 2008). In our study, there were no differences in serum bilirubin between ME‐1‐treated and control mice (ME‐1: 2.62 ± 0.28 μmol/L; control: 3.62 ± 0.27 μmol/L, mean ± SE; n = 7, P < 0.05), showing that at the dose used, ME‐1 induced no adverse effects. As shown in Table 1, mild hypomagnesemia resulted from 2 weeks of ME‐1 administration. Furthermore, serum Pi in ME‐1‐treated animals increased to a level bordering hyperphosphatemia. Other electrolytes, including Ca2+, Na+, and K+, remained unchanged.